Kazia Therapeutics Ltd's CEO Dr James Garner tells Proactive they've officially enrolled the first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021. The phase one study will focus primarily on understanding the safety, tolerability and pharmacokinetics of EVT801 across a range of doses.

Kazia Therapeutics is an oncology focused drug development company based in Sydney, Australia. In addition to Kazia’s lead programme, paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway developed to treat the most common form of brain cancer, the company is developing EVT-801, a small molecule inhibitor of VEGFR3. Preclinical data have shown EVT-801 to be active against a broad range of tumor types.

Kazia Therapeutics (KZA) is an oncology-focused drug development company. Its drug candidates are designed to treat diseases which are poorly served by existing therapies. In this video, James Garner, CEO, highlights the company’s business model, newest drug asset and progress over the next year.

Kazia Therapeutics Ltd's Dr James Garner speaks with Proactive at the ASX Small and Mid Cap Conference. Its lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

Our collaborator, Associate Professor Matt Dun talks about the new PNOC study in an article for the Hunter Medical Research Institute (HMRI).

We’re pleased to share a video interview with our CEO, Dr James Garner on Proactive Investors following the recent commencement of the GBM AGILE study, which will serve as the pivotal study for registration of our lead candidate, paxalisib.

Our CEO, Dr James Garner was recently interviewed on Ausbiz to discuss Kazia’s entitlement offer, with the company successfully completing the institutional component of the offer last week, which raised $16.4 million.

Our CEO, Dr James Garner recently conducted a video interview with Share Café following Kazia’s announcement of a collaboration with Dana-Farber Cancer Institute to investigate the use of paxalisib in primary central nervous system (CNS) lymphoma, a potential new indication for the drug.

Our CEO, Dr James Garner recently conducted video and print interviews with Share Café following the US Food and Drug Administration’s award of Rare Pediatric Disease Designation for paxalisib in Diffuse Intrinsic Pontine Glioma (DIPG) and Fast Track Designation for paxalisib in glioblastoma.

Our collaborator, Dr Matt Dun, and Kazia CEO, Dr James Garner, were interviewed on Channel 7’s Sunrise program on the development of paxalisib for Diffuse Intrinsic Pontine Glioma (DIPG) and the grant by the FDA of Rare Pediatric Disease Designation for paxalisib for the treatment of DIPG.

Our CEO, Dr James Garner recently had an article published in EQUITY magazine – the membership magazine for the Australian Shareholders Association.

This Glioblastoma (GBM) Awareness Day, Australian oncology-focused biotech company, Kazia calls for greater awareness of one of the most lethal brain cancers in the US.

Our CEO, Dr James Garner sat down with the Australian Shareholders Association to discuss the development of our lead candidate, paxalisib, for glioblastoma.

On World Brain Tumour Day (June 8), Kazia is calling for greater awareness of the signs and symptoms of brain tumours, as they can often be malignant and therefore, a potentially deadly condition.

As May draws to a close, we’d like to look back on World Ovarian Cancer Day, which was held on May 8.

Our CEO, Dr James Garner recently conducted an interview with FNN which focused on the recent interim data from Kazia’s ongoing phase II trial of paxalisib in glioblastoma.

Kazia CEO, Dr James Garner discusses the recent positive interim data from the ongoing phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising.